Gary H. Lyman, MD, MPH, FASCO, FRCP, FACP

Column

Making the Switch to Biosimilars With Clinical Pathways

03/16/2020

Gary H. Lyman , MD, MPH, FASCO, FRCP, FACP;

This section called “CME Corner,” highlights, when available, relevant continuing medical education (CME) opportunities deemed to be of use to readers. Articles include an overview of a specific area where key...

This...

03/16/2020

Journal of Clinical Pathways

Research Reports

Trend in TKI Use, Adherence, and Switching Patterns in Patients With CML: Before and After the Availability of Generic Imatinib

08/19/2020

Gary H. Lyman , MD, MPH, FASCO, FRCP, FACP;

David R. Doody , MS;

Shasank Chennupati , PharmD, MPH;

Eric J. Chow , MD, MPH;

Lena E. Winestone , MD, MSHP;

Henry J. Henk , PhD;

Pamela Morin , MBA;

Jennifer J. Wilkes , MD, MSCE;

Abstract: The therapeutic landscape for chronic myeloid leukemia (CML) has evolved substantially over the past decade, most notably with the introduction of second- and third-generation tyrosine kinase inhibitors...

...

08/19/2020

Journal of Clinical Pathways